Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05882708 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2024 to Dec 31, 2026
    • Study sites: 1 to 3
    • Study completion date: Mar 31, 2025 to May 31, 2027
    • Collaborators expanded, about 8 words
    v4
  2. Primary endpoints: 5 to 6
    • Secondary endpoints: 5 to 6
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2023 to Jun 1, 2023
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sepsis, a life-threatening syndrome, is often accompanied by tachycardia in spite of adequate volume resuscitation to correct hypovolemia and vasopressor medication to correct hypotension. Recently, relevant studies have shown that sustained tachycardia in sepsis was also related to high mortality, and appropriate control of heart rate could improve prognosis. Ivabradine reduces heart rate directly without a negative inotropic effect through inhibition of the If ionic current，which is absent from the traditional rate control drug (beta-blockers). This is a prospective, multicenter, randomized, open label study designed to compare ivabradine with placebo on the difference of heart rate and haemodynamics in patients with sepsis.
Trial Details
NCT Number NCT05882708
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Collaborators: The Third Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 Sepsis, Ivabradine, Hemodynamics, Heart Rate Control
Related terms Sepsis
Enrollment 172 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov